Compare Angi Inc (ANGI) vs CVS Health Corp (CVS) Price & Performance

ANGI trades at $4.84, down 2.42% on the day, with a bearish technical signal and mixed earnings history. Revenue has declined from $1.9B in 2022 to $1.03B in 2025, though net income turned positive in 2024-2025 before a projected loss in 2026. The stock trades at low valuation multiples (P/E 14.81, P/S 0.21), but faces challenges with negative ROE and ROA. Recent news highlights Q2 2026 earnings misses and ongoing investigations into the company.

The outlook is cautious due to declining revenue, accelerating pro user churn, and negative cash flow projections. Analyst consensus is a $7.00 price target with a 'Hold' bias, but risks include platform deterioration, legal scrutiny, and lack of clear catalysts. Upside depends on stabilizing the core marketplace and executing a viable AI strategy.

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.